New evidence indicates the possibility of a rare and serious side effect in users of Ozempic and Wegovy

New research points to an unusual side effect associated with the use of the medications Ozempic and Wegovy. The drugs, widely used in the treatment of type 2 diabetes and weight loss, may be linked to cases of stomach paralysis in some patients.
Indications of stomach paralysis in patients
Recent studies and reports from individuals have raised concerns about severe gastroparesis, also known as stomach paralysis, as a possible adverse reaction. This condition prevents the normal emptying of the stomach, causing symptoms such as persistent nausea, intense vomiting, bloating and early satiety.
How GLP-1 medications act in the body
The medicines Ozempic and Wegovy belong to the class of glucagon-like peptide-1 (GLP-1) agonists. They work by mimicking the natural hormone GLP-1, which helps control blood sugar, slows gastric emptying and promotes feelings of satiety. Although delayed stomach emptying is a therapeutic mechanism, severe paralysis goes beyond what is expected and can be debilitating.

Research into gastrointestinal risks
Health regulatory agencies in several countries, such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the United States, have already begun investigations to assess the extent and severity of these reports. The objective is to determine the frequency and causal relationship between the use of drugs and the development of severe gastroparesis.
Difference between expected effect and rare complication
It is important to distinguish the therapeutic effect of delaying gastric emptying, which contributes to weight loss and glycemic control, from a more serious complication such as stomach paralysis. While sluggishness is induced to prolong satiety, severe gastroparesis represents a significant dysfunction that impedes normal digestion and may require medical intervention. The frequency of this unusual adverse event is the focus of current investigations, given the large number of people using these medications globally for diabetes and weight management.
Guidelines for users and healthcare professionals
Medical professionals are being advised to monitor patients who report unusual and persistent gastrointestinal symptoms while taking Ozempic or Wegovy. Users of the medications should seek medical attention immediately if they experience severe nausea and vomiting, severe abdominal pain, or bloating that does not improve. Continued research and post-marketing surveillance are crucial to ensure the safety and efficacy of these important drugs.






